AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced the presentation of a poster detailing the design of its planned Phase 2 clinical trial evaluating epetraborole in patients with polycythemia vera (PV) at the 18th International Congress on Myeloproliferative Neoplasms being held October 29-30, 2026 in Brooklyn, New York.
Poster Session Details
Title: Phase 2 Study of Oral Epetraborole for Treatment of Phlebotomy-Dependent PV
Date: Thursday, October 29, 2026
Time: 5:45-7:15pm ET
Poster number: 148
About AN2 Therapeutics
AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to be active in 2026, two preclinical candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261021103616/en/
Media gallery
